(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 January 2013 (31.01.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/013302 A1

(51) International Patent Classification:
A61K 31/28 (2006.01) *G01N 33/50* (2006.01)
A61K 31/713 (2006.01) *G01N 33/68* (2006.01)
A61K 39/395 (2006.01) *A61K 31/12* (2006.01)
A61P 35/00 (2006.01) *A61K 33/24* (2006.01)

(21) International Application Number:
PCT/CA2012/000696

(22) International Filing Date:
23 July 2012 (23.07.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/510,686 22 July 2011 (22.07.2011) US

(71) Applicant *(for all designated States except US)*: **PACYLEX PHARMACEUTICALS INC.** [CA/CA]; 2600 Manulife Place, 10180 - 101 Street, Edmonton, Alberta T5J 3Y2 (CA).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BERTHIAUME, Luc, G.** [CA/CA]; 10061, 90 Avenue, Edmonton T6E 4X2 (CA). **BEAUCHAMP, Erwan** [FR/CA]; 4828 104A Street, Edmonton, T6H 5Z1, Alberta (CA). **PERIN-PANAYGAM, Conganige Maneka Anne** [LK/CA]; Unit 8, 2004 Grantham Court NW, Edmonton, T5T 6R9, Alberta (CA). **YAP, Chuiyee** [CA/CA]; 4836, 155 Avenue, Edmonton, T5Y 0C1 (CA).

(74) Agents: **VICKERS, Mark, F.** et al.; Perley-Robertson, Hill & McDougall LLP/s.r.l., 1400-340 Albert Street, Ottawa, Ontario K1R 0A5 (CA).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,

[Continued on next page]

(54) Title: SYNTHETIC LETHALITY AND THE TREATMENT OF CANCER

(57) Abstract: Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.

Figure 1



WO 2013/013302 A1

SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*